Q2 2026 saw revenue rise 5.2% year-over-year to $3.55 billion and net income attributable to shareholders increase to $265 million, with strong growth in both U.S. dialysis and ancillary services. Free cash flow and operating income improved, while labor and regulatory pressures remain key risks.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.